LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Maastricht University Medical Center
Incyte Corporation
M.D. Anderson Cancer Center
Xencor, Inc.
Incyte Corporation
Duke University